Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00680147 · ClinicalTrials.gov registry record · Phase 2

Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers

A Phase 2 study of Hpv, sponsored by Syracuse University.

Completed
Registry status
Phase 2
Development phase
614
Enrollment target
1
Study location

NCT00680147: Completed Phase 2 study of Hpv, sponsored by Syracuse University.

NCT00680147 is a Phase 2 study of Hpv that has completed, run by Syracuse University. The registered enrollment target is 614 participants, below the 2,216-participant average among 24 other Hpv trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00680147, a Phase 2 study of Hpv, has completed, sponsored by Syracuse University.

COMPLETED
Registry status
Phase 2
Development phase
614 participants
Enrollment target
1
Study location

Study Summary

This will enroll 300 mothers of teenage girls and boys to identify barriers to HPV vaccination among low-income, African-American teens.

Conditions Studied

Interventions

  • BEHAVIORAL brief informational intervention to promote HPV vaccine acceptance

Study Locations (1)

New York

  • Center for Health and Behavior, Syracuse University - Syracuse

Trial Details

FieldValue
Enrollment Target 614 participants
Start Date 2008-07
Est. Completion 2012-02
Phase Phase 2
Syracuse University

31 total trials

What the finished NCT00680147 record still lists

NCT00680147 is an interventional study that assigns participants to a tested intervention. The registered 614 participants enrollment target is mid-sized for trials with a published cap, below the 2,216-participant average among 24 other Hpv trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Hpv appearing as the primary indexed condition, and to 1 intervention - of which brief informational intervention to promote HPV vaccine acceptance is the first listed.

NCT00680147 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00680147 about?

NCT00680147 is a clinical study titled "Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers". This will enroll 300 mothers of teenage girls and boys to identify barriers to HPV vaccination among low-income, African-American teens.

What is the current status of trial NCT00680147?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 614 participants. The study started on 2008-07. Estimated completion is 2012-02.

What conditions does trial NCT00680147 study?

This clinical trial studies the following conditions: Hpv.

What interventions are being tested in trial NCT00680147?

The interventions under investigation include: brief informational intervention to promote HPV vaccine acceptance (BEHAVIORAL).

Who is sponsoring clinical trial NCT00680147?

This trial is sponsored by Syracuse University, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00680147 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hpv

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00680147's enrollment target sits among peer trials

614 8th of 24 higher than 17 of 24 other Hpv trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hpv trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03821857 · 614 participants · Phase 4

    Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

  • NCT05006716 · 614 participants · Phase 1

    A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

  • NCT06170788 · 614 participants · Phase 3

    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  • NCT07409272 · 614 participants · Phase 3

    A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00680147, the US trial registry maintained by the National Library of Medicine. NCT00680147 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.